Tannock et al. found in a prospective study of 1006 patients with metastatic prostate cancer that the chemotherapy drug docetaxel extended the overall survival (OS) of PC patients by three months and reduced PSA by more than 50% in 45% of patients [23]. Here, KLK3 is linked to metastatic prostate carcinoma.